The DEA is launching its second attempt to classify five obscure psychedelic compounds as Schedule I illegal drugs, directly clashing with the FDA’s ongoing efforts to legitimize them. While the DEA cites decades-old, non-lethal poison control data to justify a total ban, the FDA recently granted “breakthrough therapy” status to one of these exact substances as a promising treatment for postpartum depression. Critics argue this bureaucratic tug-of-war exposes an agency driven by blind prohibition, deliberately suffocating scientific research and slamming the brakes on desperately needed mental health innovations.
If you liked this post, say thanks by sharing it
